Metastatic Colorectal Adenocarcinoma Clinical Trial
Official title:
Phase II Study of Regorafenib in Good Performance Status Patients With Newly Diagnosed Metastatic Colorectal Adenocarcinoma
Verified date | January 2024 |
Source | Memorial Sloan Kettering Cancer Center |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The purpose of this study is to evaluate the good and bad effects when regorafenib is used instead of standard combination chemotherapy. It is not known if taking regorafenib versus standard chemotherapy will have better, worse or the same results.
Status | Active, not recruiting |
Enrollment | 11 |
Est. completion date | December 2024 |
Est. primary completion date | December 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Age = 18 years. - Life expectancy of at least 12 weeks (3 months). - Untreated for metastatic colorectal cancer, or progression on any first line 5-FU containing regimen (such as FOLFOX or FOLFIRI) - Histologically proven colorectal adenocarcinoma - Metastatic disease, unresectable disease involving one or more sites including liver, lung, lymph nodes and peritoneum, with each nodule measuring =3cm OR no more than two sites of disease (two nodules) >4.5 cm. - ECOG 0 or 1 - Adequate bone marrow, liver and liver function as assessed by the following laboratory requirements: - Total bilirubin = 1.5 x the upper limits of normal (ULN) - Alanine aminotransferase (ALT) and aspartate amino-transferase (AST) = 2.5 xULN (= 5 x ULN for subjects with liver involvement of their cancer) - Alkaline phosphastase limit = 2.5 x ULN (= 5 x ULN for subjects with liver involvement of their cancer) - Lipase = 1.5 x the ULN - Creatinine = 1.5 x the ULN - Platelet count = 100000 /mm3 - hemoglobin (Hb) = 9 g/dL, - absolute neutrophil count (ANC) = 1500/mm3. - Blood transfusion to meet the inclusion criteria will not be allowed. - Women of childbearing potential must have a negative serum pregnancy test performed within 7 days prior to the start of study drug. Post-menopausal women (defined as no menses for at least 1 year) and surgically sterilized women are not required to undergo a pregnancy test. - Subjects (men and women) of childbearing potential must agree to use adequate contraception beginning at the signing of the ICF until at least 3 months after the last dose of study drug. The definition of adequate contraception will be based on the judgment of the site principal investigator or a designated associate. - Subject must be able to swallow and retain oral medication. - If the patient is enrolled at MSK he/she must consent to a pre and post treatment biopsy (or have archived tissue available for the pretreatment analysis). Pretreatment archival tissue for patients enrolled outside of MSK should be submitted to MSK. If there is no archival tissue available, a repeat biopsy is not required for non-MSK patients. Exclusion Criteria: - Uncontrolled hypertension (systolic pressure >140 mm Hg or diastolic pressure > 90 mm Hg [NCI-CTCAE v4.0] on repeated measurement) despite optimal medical management. - Active or clinically significant cardiac disease including: - Congestive heart failure - New York Heart Association (NYHA) > Class II. - Active coronary artery disease. - Cardiac arrhythmias requiring anti-arrhythmic therapy other than beta blockers or digoxin. - Unstable angina (anginal symptoms at rest), new-onset angina within 3 months before randomization, or myocardial infarction within 6 months before randomization. - Evidence or history of bleeding diathesis or coagulopathy. - Any hemorrhage or bleeding event = NCI CTCAE Grade 3 within 4 weeks prior to start of study medication. - Subjects with any previously untreated or concurrent cancer that is distinct in primary site or - Recent history of prior cancer except cervical cancer in situ, treated basal cell carcinoma, or superficial bladder tumor. Subjects surviving a cancer that was curatively treated and without evidence of disease for more than 3 years before enrollment are allowed. - Known history of human immunodeficiency virus (HIV) infection or current chronic or active hepatitis B or C infection requiring treatment with antiviral therapy. - Ongoing infection > Grade 2 NCI-CTCAE v4.0. - Symptomatic metastatic brain or meningeal tumors. - Presence of a non-healing wound, non-healing ulcer, or bone fracture. - Patients with seizure disorder requiring medication. - Interstitial lung disease with ongoing signs and symptoms at the time of informed consent. - Pleural effusion or ascites that causes respiratory compromise (= NCI-CTCAE version 4.0 Grade 2 dyspnea). - History of organ allograft (including corneal transplant). - Any malabsorption condition. - Women who are pregnant or breast-feeding. - Any condition which, in the investigator's opinion, makes the subject unsuitable for trial participation. - Major surgical procedure, open biopsy, or significant traumatic injury within 28 days before start of study medication. |
Country | Name | City | State |
---|---|---|---|
United States | Memorial Sloan Kettering Cancer Center at Basking Ridge | Basking Ridge | New Jersey |
United States | Downstate Medical Center | Brooklyn | New York |
United States | Memorial Sloan Kettering Cancer Center at Commack | Commack | New York |
United States | Queens Cancer Center of Queens Hospital | Jamaica | New York |
United States | Memorial Sloan Kettering Cancer Center | New York | New York |
United States | Memorial Sloan Kettering Cancer Center at Mercy Medical Center | Rockville Centre | New York |
United States | Memorial Sloan Kettering Cancer Center Sleepy Hollow | Sleepy Hollow | New York |
Lead Sponsor | Collaborator |
---|---|
Memorial Sloan Kettering Cancer Center | Bayer, Queens Cancer Center of Queens Hospital, State University of New York - Downstate Medical Center |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | progression free survival | Response and progression will be evaluated in this study using the international criteria proposed by the RECIST 1.1 Committee. Changes in only the largest diameter (unidimensional measurement) of the tumor lesions are used in the RECIST criteria. | 16 weeks | |
Secondary | overall survival | Overall survival is defined as the time from treatment start to death or last follow up. Survival will be estimated using the Kaplan-Meier method. | 2 years | |
Secondary | disease control rate | Disease control rate (defined with RECIST 1.1 criteria at 16 weeks (2nd scan) as CR, PR or SD), will be estimated using proportions and exact binomial 95% confidence intervals provided. | 16 weeks | |
Secondary | duration of stable disease | Duration of stable disease will be defined as the time from stable disease to the time of documented progression. | 2 years | |
Secondary | toxicity | will be evaluated using the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE), version 4.0. The assessments will be based on recorded adverse events, physical examinations, and clinical laboratory assessments. Toxicity will be summarized using descriptive statistics. | 2 years |
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT01639131 -
Gemcitabine and Docetaxel in Patients With Relapsed or Refractory Metastatic Colorectal Adenocarcinoma
|
Phase 2 | |
Not yet recruiting |
NCT05356897 -
Tucatinib Combined With Trastuzumab and TAS-102 for the Treatment of HER2 Positive Metastatic Colorectal Cancer in Molecularly Selected Patients, 3T Study
|
Phase 2 | |
Completed |
NCT05869097 -
Trifluridine/Tipiracil Plus Bevacizumab Versus Trifluridine/Tipiracil Monotherapy in Refractory Metastatic Colorectal Cancer
|
||
Recruiting |
NCT05627635 -
FOLFOX and Bevacizumab in Combination With Botensilimab and Balstilimab (3B-FOLFOX) for the Treatment of Microsatellite Stable (MSS) Metastatic Colorectal Cancer
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT04362839 -
Regorafenib, Ipilimumab and Nivolumab for the Treatment of Chemotherapy Resistant Microsatellite Stable Metastatic Colorectal Cancer
|
Phase 1 | |
Recruiting |
NCT05672316 -
Botensilimab, Balstilimab and Regorafenib for the Treatment of Patients With Microsatellite Stable Metastatic Colorectal Cancer Who Have Progressed on Prior Chemotherapy
|
Phase 1/Phase 2 | |
Recruiting |
NCT02600949 -
Personalized Peptide Vaccine in Treating Patients With Advanced Pancreatic Cancer or Colorectal Cancer
|
Phase 1 | |
Active, not recruiting |
NCT04117945 -
Regorafenib, With Cetuximab or Panitumumab, for the Treatment of Unresectable, Locally Advanced, or Metastatic Colorectal Cancer
|
Phase 2 | |
Recruiting |
NCT04511039 -
Trifluridine/Tipiracil and Talazoparib for the Treatment of Patients With Locally Advanced or Metastatic Colorectal or Gastroesophageal Cancer
|
Phase 1 | |
Recruiting |
NCT06102902 -
Testing the Addition of Anti-cancer Drug, ZEN003694, to the Usual Chemotherapy Treatment, Cetuximab Plus Encorafenib, for Colorectal Cancer
|
Phase 1 | |
Completed |
NCT03043313 -
Tucatinib Plus Trastuzumab in Patients With HER2+ Colorectal Cancer
|
Phase 2 | |
Recruiting |
NCT04483219 -
Tyrosine Kinase Inhibitor (TKI) + Anti-PD-1 Antibody in TKI-responded Microsatellite Stability/Proficient Mismatch Repair (MSS/pMMR) Metastatic Colorectal Adenocarcinoma.
|
Phase 2 | |
Completed |
NCT01900717 -
Evaluation of Bevacizumab in Combination With First-Line Chemotherapy in Patients Aged 75 Years of Older With Metastatic Colorectal Adenocarcinoma (Prodige20)
|
Phase 2 | |
Active, not recruiting |
NCT05312398 -
CAPRI 2 GOIM Study: Investigate the Efficacy and Safety of a Bio-marker Driven Cetuximab-based Treatment Regimen
|
Phase 2 | |
Not yet recruiting |
NCT06336902 -
Botensilimab Plus Balstilimab and Fasting Mimicking Diet Plus Vitamin C for Patients With KRAS-Mutant Metastatic Colorectal Cancer
|
Phase 1 | |
Completed |
NCT05942768 -
Anti-PD-1 Antibody Plus Regorafenib in Refractory Microsatellite Stable Metastatic Colorectal Cancer
|
||
Completed |
NCT06031376 -
Fruquintinib With PD-1 Inhibitors Versus TAS-102 With Bevacizumab in Late-Line mCRC
|
||
Not yet recruiting |
NCT06195670 -
Clinical Study of Short-course Radiotherapy Followed by Fruquintinib Plus Sintilimab vs Bevacizumab Plus Capecitabine as First Line Treatment in Advanced mCRC
|
Phase 1/Phase 2 | |
Recruiting |
NCT02997228 -
Combination Chemotherapy, Bevacizumab, and/or Atezolizumab in Treating Patients With Deficient DNA Mismatch Repair Metastatic Colorectal Cancer, the COMMIT Study
|
Phase 3 | |
Recruiting |
NCT05673148 -
Testing the Addition of Total Ablative Therapy to Usual Systemic Therapy Treatment for Limited Metastatic Colorectal Cancer, The ERASur Study
|
Phase 3 |